Submodule
Mineral Regulation
Calcium and phosphate are controlled by coordinated signaling among bone, kidney, intestine, and parathyroid tissue.
- PTH and calcium-sensing receptor
- Vitamin D activation
- FGF23 and phosphate handling
- Bone turnover and mineral balance
Track calcium through the feedback loop
A fall in ionized calcium stimulates parathyroid hormone secretion. PTH increases renal calcium reabsorption, promotes phosphate excretion, stimulates renal formation of calcitriol, and supports release of mineral from bone when sustained. The calcium-sensing receptor helps the parathyroid gland and kidney detect extracellular calcium.
Separate vitamin D production from effect
Vitamin D is hydroxylated first in the liver to 25-hydroxyvitamin D, the principal marker of body stores, then in the kidney to active 1,25-dihydroxyvitamin D. Calcitriol increases intestinal absorption of calcium and phosphate. Kidney disease, low substrate, magnesium deficiency, and abnormal PTH signaling can disrupt the pathway at different points.
Use FGF23 to explain phosphate control
FGF23 is released mainly by osteocytes when phosphate load or calcitriol signaling rises. It lowers renal phosphate reabsorption and suppresses calcitriol production. In chronic kidney disease, phosphate retention, FGF23 elevation, low calcitriol, hypocalcemic pressure, and secondary hyperparathyroidism can coexist before serum phosphate becomes markedly high.
Quick check
Submodule
Calcium Measurement and Diagnostic Reasoning
The clinically active fraction is ionized calcium. Total calcium is influenced by albumin, pH, complexing anions, and the measurement context.
- Ionized versus total calcium
- Albumin adjustment limits
- PTH-directed differential
- Magnesium, phosphate, vitamin D, and kidney data
Albumin and pH can change the fractions. Measure ionized calcium when that distinction changes care.
Know what the laboratory measured
Roughly half of circulating calcium is ionized and biologically active. The remainder is protein bound or complexed. Total calcium can look low when albumin is low even if ionized calcium is normal. Alkalemia increases albumin binding and can lower ionized calcium, while acidemia can increase the ionized fraction.
Use correction formulas cautiously
A common estimate in mg/dL adds 0.8 times the difference between 4 g/dL and measured albumin to total calcium. The equation can be inaccurate in critical illness, kidney disease, marked hypoalbuminemia, and abnormal pH. Direct ionized calcium is preferred when precision matters or the estimate conflicts with the clinical picture.
Let PTH organize the differential
Hypercalcemia with an elevated or inappropriately normal PTH suggests a PTH-dependent process such as primary or tertiary hyperparathyroidism, while suppressed PTH shifts attention toward malignancy, vitamin D excess, granulomatous disease, medications, or other causes. In hypocalcemia, measure magnesium, phosphate, kidney function, PTH, and vitamin D to distinguish impaired hormone response, deficiency, sequestration, and loss.
Quick check
Submodule
Hypocalcemia
Symptoms, ECG effects, rate of decline, and cause determine urgency more reliably than a total calcium value alone.
- Tetany, seizures, and QT prolongation
- IV calcium products
- Oral calcium and vitamin D
- Magnesium and cause correction
Recognize a calcium emergency
Perioral or digital paresthesia, carpopedal spasm, tetany, laryngospasm, seizure, prolonged QT, and arrhythmia can signal clinically important hypocalcemia. Symptoms depend on ionized calcium and speed of decline. Severe symptoms require urgent monitored treatment even before every etiologic result is available.
Administer IV calcium safely
Current calcium gluconate labeling indicates it for acute symptomatic hypocalcemia and requires dilution, a secure IV line, controlled administration, and monitoring. Ten percent calcium gluconate contains 9.3 mg of elemental calcium per mL. Calcium chloride provides more elemental calcium per volume but is more irritating and generally requires central access when used for calcium replacement.
Correct the mechanism
Stable or mild disease may be managed with oral calcium and vitamin D according to cause and local protocol. Hypoparathyroidism may require active vitamin D because renal activation is insufficient without PTH signaling. Vitamin D deficiency requires repletion. Hypomagnesemia must be corrected because it can suppress PTH release and produce resistance to PTH.
Protect the kidney during chronic therapy
Chronic hypoparathyroidism care aims to control symptoms without driving excessive urinary calcium. Follow serum calcium, phosphate, magnesium, kidney function, and urinary calcium as appropriate. A thiazide can reduce urinary calcium in selected patients. Palopegteriparatide is an FDA-approved PTH replacement option for adults with hypoparathyroidism, but it is not an acute rescue treatment and requires individualized calcium monitoring during titration.
Prevent treatment complications
Follow symptoms, ECG, ionized or total calcium as appropriate, magnesium, phosphate, kidney function, and the IV site. Rapid calcium administration can cause hypotension or arrhythmia. Calcium can precipitate with bicarbonate or phosphate in the same line, so compatibility and line management require explicit review.
Quick check
Submodule
Hypercalcemia
Volume status, neurologic and cardiac toxicity, kidney function, PTH, and the underlying mechanism shape acute and definitive treatment.
- PTH-dependent and independent causes
- Hydration and urgent stabilization
- Calcitonin, bisphosphonates, and denosumab
- Cause-specific therapy and monitoring
Determine severity and mechanism
Hypercalcemia can cause polyuria, dehydration, kidney injury, constipation, weakness, cognitive change, shortened QT, and dysrhythmia. Check medication and supplement exposure, volume status, kidney function, phosphate, PTH, and a confirmatory calcium measurement. PTH is the central first branch in the etiologic workup.
Restore volume thoughtfully
Isotonic crystalloid can correct volume depletion and improve renal calcium clearance, but the amount and rate must reflect heart and kidney function. Loop diuretics are not routine calcium-lowering therapy and are generally reserved for fluid overload after adequate volume has been restored. Dialysis is considered for selected severe cases with kidney failure, refractory disease, or inability to tolerate fluids.
Match onset to the clinical need
Calcitonin acts rapidly but loses effect through tachyphylaxis, so the Endocrine Society limits its use in severe hypercalcemia of malignancy to 48 to 72 hours. IV bisphosphonates and denosumab reduce osteoclast-mediated calcium release more slowly. The guideline recommends an IV bisphosphonate or denosumab for adults with hypercalcemia of malignancy and suggests denosumab over an IV bisphosphonate, while recognizing low-certainty evidence.
Treat the source
Calcitriol-mediated hypercalcemia may respond to glucocorticoids. Primary hyperparathyroidism may require surgery after stabilization. Hypercalcemia related to medication or supplements requires withdrawal and reassessment. Antiresorptive therapy can produce hypocalcemia, especially with vitamin D deficiency or severe kidney impairment, so mineral status and organ function must be followed.
Quick check
Submodule
Hypophosphatemia
Low phosphate may reflect redistribution, reduced absorption, or renal loss. Severe depletion can impair respiratory, cardiac, neurologic, and hematologic function.
- Redistribution and refeeding
- Renal and gastrointestinal loss
- Oral versus IV replacement
- Potassium and sodium phosphate selection
Then ask: Is it symptomatic? Can the gut be used? Which cation is safe? What does kidney function permit?
Classify the mechanism
Insulin, respiratory alkalosis, catecholamines, and refeeding can shift phosphate into cells. Poor intake, malabsorption, antacids, or binders can reduce absorption. Hyperparathyroidism, tubular disorders, and selected medications can increase renal loss. Urine phosphate assessment can help when the mechanism remains unclear. Ferric carboxymaltose can produce FGF23-mediated renal phosphate wasting, including serious symptomatic hypophosphatemia after repeated exposure.
Recognize severe depletion
Profound hypophosphatemia can cause weakness, respiratory failure, rhabdomyolysis, encephalopathy, seizures, hemolysis, platelet dysfunction, and impaired myocardial performance. A laboratory threshold should never replace assessment of symptoms, duration, organ function, and concurrent potassium, magnesium, and calcium abnormalities.
Choose route and product deliberately
Oral replacement is preferred for stable, less severe disease when absorption is reliable. IV replacement is reserved for severe, symptomatic, or enterally inaccessible cases and follows institutional protocols. Potassium phosphate adds potassium, while sodium phosphate adds sodium. The patient's potassium, sodium, kidney function, access, infusion rate, and calcium concentration determine the safer choice.
Monitor for overcorrection
IV phosphate can cause hypocalcemia, hypotension, acute kidney injury, hyperphosphatemia, and calcium-phosphate precipitation. Repeat phosphate, calcium, potassium, magnesium, and kidney function at an acuity-matched interval. Avoid co-infusing calcium and phosphate through the same line without verified compatibility.
Quick check
Submodule
Hyperphosphatemia and CKD Mineral Bone Disorder
Hyperphosphatemia can follow reduced kidney excretion, acute cell breakdown, hormone disorders, or exogenous phosphate. In chronic kidney disease it becomes part of a dynamic disorder involving calcium, PTH, vitamin D, bone, and vascular calcification.
- Acute phosphate load and cell breakdown
- Serial calcium, phosphate, and PTH trends
- Phosphate binders
- Secondary hyperparathyroidism and dialysis
Recognize acute phosphate toxicity
Tumor lysis, rhabdomyolysis, severe tissue injury, exogenous phosphate, kidney failure, and hypoparathyroidism can raise phosphate. Acute hyperphosphatemia may lower ionized calcium and promote calcium-phosphate deposition. Treat the cause, assess kidney function and ECG risk, and use dialysis when severe toxicity and kidney failure warrant it. Give calcium for clinically important hypocalcemic toxicity, but avoid indiscriminate calcium loading when precipitation risk is high.
Treat a pattern, not a single number
KDIGO recommends basing CKD mineral and bone disorder decisions on serial assessments of phosphate, calcium, and PTH considered together. The guideline suggests lowering elevated phosphate toward the normal range and avoiding hypercalcemia, while acknowledging that evidence for hard outcomes remains limited.
Reduce absorbable phosphate
Dietary counseling should consider source as well as total amount. Inorganic phosphate additives are highly absorbable, animal sources are generally more available than plant phytate, and excessive restriction can compromise nutrition. Phosphate binders work in the gastrointestinal tract and must be taken with meals or snacks that contain phosphate.
Choose binders by patient risk
Calcium acetate and calcium carbonate add calcium load. Sevelamer, lanthanum, ferric citrate, sucroferric oxyhydroxide, and other options differ in pill burden, adverse effects, iron effects, interactions, and cost. KDIGO suggests restricting calcium-based binder dose in adults receiving phosphate-lowering therapy, especially when calcium load or calcification risk is concerning. Aluminum binders are avoided for long-term use because aluminum can accumulate and cause toxicity.
Coordinate hormone and dialysis therapy
Persistent secondary hyperparathyroidism requires evaluation for hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency. Vitamin D analogs and calcimimetics can alter calcium and phosphate in opposite directions and require monitoring. Dialysis removes phosphate incompletely between treatments, so adherence to dialysis, nutrition, and binder timing all matter.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- KDIGO 2017 CKD mineral and bone disorder guideline update
- Endocrine Society guideline on hypercalcemia of malignancy
- Society for Endocrinology guidance on acute hypocalcemia
- Society for Endocrinology guidance on acute hypercalcemia
- FDA label: Calcium gluconate injection
- FDA label: Zoledronic acid injection
- FDA label: Denosumab
- FDA label: Palopegteriparatide
- FDA label: Ferric carboxymaltose